| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author (s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu and Lin Wang |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Leading Talent Project of Yunnan Province |
L201622 |
|
| Corresponding Author |
Lin Wang, PhD, Professor, Surgical Oncologist, Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Kunming Medical University, 1168 Chunrongxi Rd, Kunming 650500, Yunnan Province, China. wanglin@acgxg.com |
| Key Words |
Sorafenib; Hepatocellular carcinoma; Transarterial chemoembolization; Overall survival; Adverse reaction |
| Core Tip |
Hepatocellular carcinoma (HCC) is a common digestive tract malignancy. Transarterial chemoembolization (TACE) is the standard treatment for intermediate-stage HCC, and it has a limited beneficial effect. To evaluate the safety and efficacy of sorafenib plus TACE treatment for intermediate-stage HCC. Sixty-seven patients with intermediate-stage HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. This study confirms that sorafenib plus TACE treatment for intermediate-stage HCC significantly prolonged the median overall survival of patients compared to TACE treatment alone. Moreover, this new treatment approach showed tolerable toxicity. |
| Publish Date |
2018-05-16 07:38 |
| Citation |
Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83 |
| URL |
http://www.wjgnet.com/2307-8960/full/v6/i5/74.htm |
| DOI |
http://dx.doi.org/10.12998/wjcc.v6.i5.74 |
